company background image
UR9 logo

Clinuvel Pharmaceuticals DB:UR9 Stock Report

Last Price

€8.76

Market Cap

€434.8m

7D

1.8%

1Y

-25.9%

Updated

28 Mar, 2024

Data

Company Financials +

Clinuvel Pharmaceuticals Limited

DB:UR9 Stock Report

Market Cap: €434.8m

UR9 Stock Overview

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally.

UR9 fundamental analysis
Snowflake Score
Valuation3/6
Future Growth2/6
Past Performance3/6
Financial Health6/6
Dividends0/6

Clinuvel Pharmaceuticals Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Clinuvel Pharmaceuticals
Historical stock prices
Current Share PriceAU$8.76
52 Week HighAU$12.80
52 Week LowAU$7.90
Beta0.74
1 Month Change7.62%
3 Month Change-11.75%
1 Year Change-25.94%
3 Year Change-51.34%
5 Year Change-49.29%
Change since IPO68.42%

Recent News & Updates

Recent updates

Shareholder Returns

UR9DE BiotechsDE Market
7D1.8%1.0%1.8%
1Y-25.9%33.7%5.7%

Return vs Industry: UR9 underperformed the German Biotechs industry which returned 34.7% over the past year.

Return vs Market: UR9 underperformed the German Market which returned 7% over the past year.

Price Volatility

Is UR9's price volatile compared to industry and market?
UR9 volatility
UR9 Average Weekly Movement6.3%
Biotechs Industry Average Movement5.7%
Market Average Movement4.8%
10% most volatile stocks in DE Market9.9%
10% least volatile stocks in DE Market2.4%

Stable Share Price: UR9 has not had significant price volatility in the past 3 months.

Volatility Over Time: UR9's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1987n/aPhilippe Wolgenhttps://www.clinuvel.com

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company’s pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide.

Clinuvel Pharmaceuticals Limited Fundamentals Summary

How do Clinuvel Pharmaceuticals's earnings and revenue compare to its market cap?
UR9 fundamental statistics
Market cap€434.82m
Earnings (TTM)€18.21m
Revenue (TTM)€49.39m

23.9x

P/E Ratio

8.8x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
UR9 income statement (TTM)
RevenueAU$81.76m
Cost of RevenueAU$6.70m
Gross ProfitAU$75.06m
Other ExpensesAU$44.90m
EarningsAU$30.15m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)0.60
Gross Margin91.80%
Net Profit Margin36.88%
Debt/Equity Ratio0%

How did UR9 perform over the long term?

See historical performance and comparison

Dividends

0.3%

Current Dividend Yield

8%

Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.